Using genetics to predict patient response to platinum-based chemotherapy-Reference-Cited by-同舟云学术

Using genetics to predict patient response to platinum-based chemotherapy

Published:2017-01-02 Issue:1 Volume:2 Page:21-32
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

Karachaliou Niki¹,Moreno Maria de los Llanos Gil²,Sosa Aaron E.¹,Santarpia Mariacarmela³,Lazzari Chiara⁴,Capote Alejandra Rodriguez⁵,Massuti Bartomeu⁶,Rosell Rafael²⁷⁸

Affiliation:

1. Instituto of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain

2. Instituto of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain

3. Medical Oncology Unit, Department of Human Pathology ‘‘G. Barresi’’, University of Messina, Messina, Italy

4. Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy

5. Medical Oncology Department, University Hospital of Canary Islands, Tenerife, Spain

6. Medical Oncology Service, Hospital General de Alicante, Alicante, Spain

7. Laboratory of Cancer Molecular Biology, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain

8. Cancer Biology & Precision Medicine Laboratory, Catalan Institute of Oncology (ICO), Germans Trias i Pujol University Hospital, Badalona, Spain

Funder

La Caixa Foundation

Red Tematica de Investigacion Cooperativa en Cancer (RTICC)

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2017.1298969

Reference110 articles.

1. Platinum Compounds: a New Class of Potent Antitumour Agents

2. Cellular processing of platinum anticancer drugs

3. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs

4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

5. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of variations in the Fanconi anemia complementation group and prognosis in Non–small cell lung cancer patients with Platinum-based chemotherapy;Gene;2022-05

2. Pharmacogenetics: Knowledge assessment amongst Syrian pharmacists and physicians;BMC Health Services Research;2021-10-01

3. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib;JTO Clinical and Research Reports;2021-03

4. Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN® System Comprehensive Approach;Pharmaceuticals;2021-01-15

5. Impact of the APE1 Redox Function Inhibitor E3330 in Non-Small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and Invasion;Antioxidants;2020-06-24